<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AI Disruption Forecast: Sun Pharma ‚Äî Analyst Perspective | The 2030 Intelligence Report</title>
    <meta name="description" content="From: The 2030 Report">
    <meta property="og:title" content="ENTITY: SUN PHARMACEUTICAL INDUSTRIES LIMITED">
    <meta property="og:description" content="From: The 2030 Report">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://ai2030report.com/articles/companies-india-sun-pharma-sunpharma-investor.html">
    <meta property="og:image" content="https://ai2030report.com/og/companies-india-sun-pharma-sunpharma-investor.png">
    <meta property="og:image:width" content="1200">
    <meta property="og:image:height" content="630">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="ENTITY: SUN PHARMACEUTICAL INDUSTRIES LIMITED">
    <meta name="twitter:description" content="From: The 2030 Report">
    <meta name="twitter:image" content="https://ai2030report.com/og/companies-india-sun-pharma-sunpharma-investor.png">
    <link rel="canonical" href="https://ai2030report.com/articles/companies-india-sun-pharma-sunpharma-investor.html">
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "Article",
        "headline": "ENTITY: SUN PHARMACEUTICAL INDUSTRIES LIMITED",
        "description": "From: The 2030 Report",
        "url": "https://ai2030report.com/articles/companies-india-sun-pharma-sunpharma-investor.html",
        "author": {
            "@type": "Organization",
            "name": "The 2030 Intelligence Report"
        },
        "publisher": {
            "@type": "Organization",
            "name": "The 2030 Intelligence Report"
        }
    }
    </script>
    <link rel="icon" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect rx='20' width='100' height='100' fill='%233b82f6'/><text x='50' y='70' font-size='55' font-weight='700' text-anchor='middle' fill='white'>30</text></svg>">
    <style>
:root {
    --bg-primary: #0a0a0f;
    --bg-secondary: #111118;
    --bg-card: #16161f;
    --bg-card-hover: #1c1c28;
    --border: #2a2a3a;
    --text-primary: #e4e4ef;
    --text-secondary: #9494a8;
    --text-muted: #6b6b80;
    --accent-blue: #3b82f6;
    --accent-purple: #8b5cf6;
    --accent-amber: #f59e0b;
    --accent-green: #10b981;
    --accent-red: #ef4444;
    --accent-cyan: #06b6d4;
    --gradient-1: linear-gradient(135deg, #3b82f6 0%, #8b5cf6 100%);
}

* {
    margin: 0;
    padding: 0;
    box-sizing: border-box;
}

html {
    scroll-behavior: smooth;
}

body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
    background-color: var(--bg-primary);
    color: var(--text-primary);
    line-height: 1.6;
    letter-spacing: -0.3px;
}

a {
    color: var(--accent-blue);
    text-decoration: none;
    transition: color 0.2s ease;
}

a:hover {
    color: var(--accent-purple);
}

button {
    background: none;
    border: none;
    cursor: pointer;
    font-family: inherit;
}

/* Header */
.site-header {
    position: sticky;
    top: 0;
    z-index: 1000;
    background: rgba(10, 10, 15, 0.95);
    backdrop-filter: blur(10px);
    border-bottom: 1px solid var(--border);
}

.header-inner {
    max-width: 1400px;
    margin: 0 auto;
    padding: 1rem 2rem;
    display: flex;
    align-items: center;
    justify-content: space-between;
}

.site-logo {
    display: flex;
    align-items: center;
    gap: 0.5rem;
    font-weight: 700;
    font-size: 1.5rem;
    color: var(--text-primary);
    text-decoration: none;
}

.logo-mark {
    width: 2rem;
    height: 2rem;
    background: var(--gradient-1);
    border-radius: 0.5rem;
    display: flex;
    align-items: center;
    justify-content: center;
    color: white;
    font-weight: 700;
    font-size: 1.2rem;
}

.logo-text {
    display: flex;
    flex-direction: column;
    gap: 0.125rem;
}

.logo-text-main {
    font-size: 1rem;
}

.logo-text-sub {
    font-size: 0.65rem;
    color: var(--text-secondary);
    letter-spacing: 0.5px;
}

.nav-links {
    display: flex;
    gap: 2rem;
    list-style: none;
}

.nav-links a {
    color: var(--text-secondary);
    font-size: 0.95rem;
    font-weight: 500;
    transition: color 0.2s ease;
}

.nav-links a:hover {
    color: var(--text-primary);
}

.nav-toggle {
    display: none;
    flex-direction: column;
    gap: 0.4rem;
    padding: 0.5rem;
}

.nav-toggle span {
    width: 1.5rem;
    height: 2px;
    background: var(--text-primary);
    transition: all 0.3s ease;
}

/* Hero Section */
.hero {
    max-width: 1400px;
    margin: 0 auto;
    padding: 4rem 2rem;
    text-align: center;
}

.hero h1 {
    font-size: 3rem;
    margin-bottom: 0.5rem;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.hero .tagline {
    font-size: 1.25rem;
    color: var(--text-secondary);
    margin-bottom: 2rem;
}

.hero-stats {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
    gap: 2rem;
    margin-top: 3rem;
    padding-top: 3rem;
    border-top: 1px solid var(--border);
}

.stat {
    text-align: center;
}

.stat-number {
    font-size: 2.5rem;
    font-weight: 700;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.stat-label {
    font-size: 0.9rem;
    color: var(--text-secondary);
    margin-top: 0.5rem;
}

/* Search and Filter */
.search-container {
    max-width: 1400px;
    margin: 2rem auto;
    padding: 0 2rem;
}

.search-box {
    width: 100%;
    padding: 1rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-primary);
    font-size: 1rem;
    margin-bottom: 1.5rem;
}

.search-box::placeholder {
    color: var(--text-muted);
}

.filter-buttons {
    display: flex;
    gap: 1rem;
    flex-wrap: wrap;
    margin-bottom: 2rem;
}

.filter-btn {
    padding: 0.75rem 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-secondary);
    cursor: pointer;
    font-weight: 500;
    transition: all 0.2s ease;
}

.filter-btn:hover,
.filter-btn.active {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

/* Article Grid */
.article-grid {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem 4rem 2rem;
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(350px, 1fr));
    gap: 2rem;
}

.article-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 1.5rem;
    transition: all 0.3s ease;
    display: flex;
    flex-direction: column;
    cursor: pointer;
}

.article-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
    transform: translateY(-2px);
}

.card-meta {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 1rem;
    flex-wrap: wrap;
    gap: 0.5rem;
}

.card-badge {
    display: inline-flex;
    align-items: center;
    gap: 0.35rem;
    padding: 0.35rem 0.75rem;
    background: rgba(59, 130, 246, 0.15);
    border-radius: 0.25rem;
    font-size: 0.75rem;
    font-weight: 600;
    text-transform: uppercase;
    letter-spacing: 0.5px;
}

.badge-countries {
    background: rgba(59, 130, 246, 0.15);
    color: #3b82f6;
}

.badge-companies {
    background: rgba(139, 92, 246, 0.15);
    color: #8b5cf6;
}

.badge-sectors {
    background: rgba(245, 158, 11, 0.15);
    color: #f59e0b;
}

.badge-actions {
    background: rgba(16, 185, 129, 0.15);
    color: #10b981;
}

.badge-guides {
    background: rgba(6, 182, 212, 0.15);
    color: #06b6d4;
}

.badge-data {
    background: rgba(239, 68, 68, 0.15);
    color: #ef4444;
}

.card-audience {
    display: inline-flex;
    align-items: center;
    gap: 0.35rem;
    padding: 0.35rem 0.75rem;
    background: rgba(148, 148, 168, 0.15);
    border-radius: 0.25rem;
    font-size: 0.75rem;
    font-weight: 600;
    color: var(--text-secondary);
}

.card-title {
    font-size: 1.25rem;
    font-weight: 600;
    color: var(--text-primary);
    margin-bottom: 0.75rem;
    line-height: 1.3;
    flex-grow: 1;
}

.card-excerpt {
    font-size: 0.95rem;
    color: var(--text-secondary);
    margin-bottom: 1rem;
    line-height: 1.5;
}

.card-footer {
    display: flex;
    justify-content: space-between;
    align-items: center;
    padding-top: 1rem;
    border-top: 1px solid var(--border);
    color: var(--text-muted);
    font-size: 0.9rem;
}

.read-time {
    display: flex;
    align-items: center;
    gap: 0.35rem;
}

/* Entity Cards (Browse Pages) */
.entity-grid {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem 4rem 2rem;
    display: grid;
    grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
    gap: 2rem;
}

.entity-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2rem;
    text-align: center;
    transition: all 0.3s ease;
}

.entity-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
    transform: translateY(-2px);
}

.entity-icon {
    font-size: 3rem;
    margin-bottom: 1rem;
}

.entity-card h3 {
    font-size: 1.5rem;
    color: var(--text-primary);
    margin-bottom: 0.5rem;
}

.entity-card p {
    color: var(--text-secondary);
    margin-bottom: 1.5rem;
    font-size: 0.95rem;
}

.entity-card a {
    display: inline-block;
    padding: 0.75rem 1.5rem;
    background: var(--accent-blue);
    color: white;
    border-radius: 0.25rem;
    font-weight: 600;
    transition: all 0.2s ease;
}

.entity-card a:hover {
    background: var(--accent-purple);
}

/* Entity Landing Page */
.entity-landing {
    max-width: 1400px;
    margin: 0 auto;
    padding: 0 2rem;
}

.entity-hero-section {
    padding: 3rem 0 2rem 0;
    border-bottom: 1px solid var(--border);
    margin-bottom: 2rem;
}

.entity-hero-content {
    display: flex;
    align-items: center;
    gap: 2rem;
}

.entity-hero-icon {
    font-size: 4rem;
}

.entity-hero-title {
    font-size: 2.5rem;
    margin-bottom: 0.5rem;
    background: var(--gradient-1);
    -webkit-background-clip: text;
    -webkit-text-fill-color: transparent;
    background-clip: text;
}

.entity-hero-section p {
    color: var(--text-secondary);
    font-size: 1.1rem;
}

/* Active nav item */
.nav-links a.nav-active {
    color: var(--accent-blue);
}

/* Clickable entity card */
.entity-card {
    cursor: pointer;
}

/* Article Page */
.article-page {
    max-width: 900px;
    margin: 0 auto;
    padding: 2rem;
}

.breadcrumb {
    display: flex;
    gap: 0.5rem;
    margin-bottom: 2rem;
    font-size: 0.9rem;
    color: var(--text-secondary);
    flex-wrap: wrap;
}

.breadcrumb a {
    color: var(--accent-blue);
}

.breadcrumb a:hover {
    color: var(--accent-purple);
}

.breadcrumb span {
    margin: 0 0.5rem;
}

.article-header {
    margin-bottom: 2rem;
}

.article-meta-bar {
    display: flex;
    justify-content: space-between;
    align-items: center;
    margin-bottom: 2rem;
    padding-bottom: 1.5rem;
    border-bottom: 1px solid var(--border);
    flex-wrap: wrap;
    gap: 1rem;
}

.article-category {
    display: flex;
    gap: 0.75rem;
    align-items: center;
}

.entity-name-display {
    font-size: 1.3rem;
    font-weight: 600;
    color: var(--text-primary);
    margin-bottom: 1.5rem;
    padding-bottom: 1rem;
    border-bottom: 1px solid var(--border);
}

/* Sibling Navigation */
.sibling-nav {
    margin-bottom: 2rem;
    padding-bottom: 1.5rem;
    border-bottom: 1px solid var(--border);
}

.sibling-nav-label {
    font-size: 0.95rem;
    font-weight: 600;
    color: var(--text-secondary);
    margin-bottom: 1rem;
}

.sibling-pills {
    display: flex;
    gap: 0.75rem;
    flex-wrap: wrap;
}

.sibling-pill {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    padding: 0.6rem 1.2rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 2rem;
    color: var(--text-secondary);
    font-size: 0.9rem;
    font-weight: 500;
    transition: all 0.2s ease;
    white-space: nowrap;
    cursor: pointer;
}

.sibling-pill a {
    color: inherit;
    text-decoration: none;
}

.sibling-pill:hover {
    border-color: var(--accent-blue);
    color: var(--accent-blue);
}

.sibling-pill.active {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.sibling-pill.active a {
    color: white;
}

/* Share Bar */
.share-bar {
    display: flex;
    gap: 1rem;
    align-items: center;
    margin-bottom: 2rem;
    padding: 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    flex-wrap: wrap;
}

.share-bar-label {
    font-size: 0.9rem;
    font-weight: 600;
    color: var(--text-secondary);
    margin-right: 0.5rem;
}

.share-btn {
    display: inline-flex;
    align-items: center;
    justify-content: center;
    padding: 0.7rem 1.2rem;
    background: var(--bg-secondary);
    border: 1px solid var(--border);
    border-radius: 0.4rem;
    color: var(--text-secondary);
    font-size: 0.9rem;
    font-weight: 500;
    cursor: pointer;
    transition: all 0.2s ease;
    white-space: nowrap;
}

.share-btn:hover {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.share-btn.copied {
    background: var(--accent-green);
    border-color: var(--accent-green);
    color: white;
}

.article-content {
    font-size: 1.05rem;
    line-height: 1.8;
    color: var(--text-primary);
}

.article-content h1 {
    font-size: 2.5rem;
    margin-bottom: 1.5rem;
    line-height: 1.2;
    margin-top: 2rem;
}

.article-content h1:first-child {
    margin-top: 0;
}

.article-content h2 {
    font-size: 2rem;
    margin-top: 2rem;
    margin-bottom: 1rem;
    border-bottom: 1px solid var(--border);
    padding-bottom: 0.5rem;
}

.article-content h3 {
    font-size: 1.5rem;
    margin-top: 1.5rem;
    margin-bottom: 0.75rem;
}

.article-content p {
    margin-bottom: 1.25rem;
}

.article-content ul,
.article-content ol {
    margin-left: 2rem;
    margin-bottom: 1.25rem;
}

.article-content li {
    margin-bottom: 0.5rem;
}

.article-content table {
    width: 100%;
    border-collapse: collapse;
    margin-bottom: 1.25rem;
    border: 1px solid var(--border);
}

.article-content th {
    background: var(--bg-secondary);
    padding: 1rem;
    text-align: left;
    font-weight: 600;
    border: 1px solid var(--border);
}

.article-content td {
    padding: 1rem;
    border: 1px solid var(--border);
}

.article-content blockquote {
    margin-left: 0;
    padding-left: 1.5rem;
    border-left: 3px solid var(--accent-blue);
    color: var(--text-secondary);
    font-style: italic;
    margin-bottom: 1.25rem;
}

.article-content hr {
    border: none;
    height: 1px;
    background: var(--border);
    margin: 2rem 0;
}

.article-content code {
    background: var(--bg-card);
    padding: 0.25rem 0.5rem;
    border-radius: 0.25rem;
    font-family: "Courier New", monospace;
    font-size: 0.9em;
    color: var(--accent-cyan);
}

.article-content pre {
    background: var(--bg-card);
    padding: 1.5rem;
    border-radius: 0.5rem;
    overflow-x: auto;
    margin-bottom: 1.25rem;
    border: 1px solid var(--border);
}

.article-content pre code {
    background: none;
    padding: 0;
    color: var(--text-primary);
}

/* More in Category */
.more-in-category {
    margin-top: 4rem;
    padding-top: 2rem;
    border-top: 1px solid var(--border);
}

.more-in-category h3 {
    font-size: 1.5rem;
    margin-bottom: 2rem;
}

.more-grid {
    display: grid;
    grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
    gap: 2rem;
}

.more-card {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 1.5rem;
    transition: all 0.3s ease;
}

.more-card:hover {
    background: var(--bg-card-hover);
    border-color: var(--accent-blue);
}

.more-card h4 {
    font-size: 1.1rem;
    margin-bottom: 0.5rem;
    color: var(--text-primary);
}

.more-card p {
    font-size: 0.9rem;
    color: var(--text-secondary);
    margin-bottom: 1rem;
}

.more-card a {
    font-weight: 600;
}

/* Footer */
.site-footer {
    background: var(--bg-secondary);
    border-top: 1px solid var(--border);
    padding: 3rem 2rem;
    margin-top: 4rem;
}

.footer-content {
    max-width: 1400px;
    margin: 0 auto;
}

.footer-disclaimer {
    color: var(--text-secondary);
    font-size: 0.9rem;
    margin-bottom: 1.5rem;
}

.footer-links {
    display: flex;
    gap: 2rem;
    flex-wrap: wrap;
    margin-bottom: 1.5rem;
}

.footer-links a {
    color: var(--text-secondary);
    font-size: 0.9rem;
}

.footer-links a:hover {
    color: var(--text-primary);
}

.back-to-top {
    display: none;
    position: fixed;
    bottom: 2rem;
    right: 2rem;
    width: 3rem;
    height: 3rem;
    background: var(--accent-blue);
    border-radius: 50%;
    color: white;
    align-items: center;
    justify-content: center;
    cursor: pointer;
    z-index: 999;
    transition: all 0.3s ease;
}

.back-to-top:hover {
    background: var(--accent-purple);
    transform: translateY(-2px);
}

.back-to-top.visible {
    display: flex;
}

/* Feedback Widget */
.feedback-widget {
    position: fixed;
    bottom: 2rem;
    left: 2rem;
    z-index: 1000;
}
.feedback-toggle {
    background: var(--accent-blue);
    color: white;
    border: none;
    padding: 0.6rem 1.2rem;
    border-radius: 2rem;
    cursor: pointer;
    font-size: 0.9rem;
    font-weight: 600;
    box-shadow: 0 4px 15px rgba(59,130,246,0.4);
    transition: all 0.3s ease;
}
.feedback-toggle:hover {
    background: var(--accent-purple);
    transform: translateY(-2px);
}
.feedback-panel {
    display: none;
    position: absolute;
    bottom: 3.5rem;
    left: 0;
    width: 340px;
    background: var(--surface);
    border: 1px solid var(--border);
    border-radius: 1rem;
    box-shadow: 0 10px 40px rgba(0,0,0,0.3);
    overflow: hidden;
}
.feedback-panel.open {
    display: block;
    animation: feedbackSlideUp 0.25s ease;
}
@keyframes feedbackSlideUp {
    from { opacity: 0; transform: translateY(10px); }
    to { opacity: 1; transform: translateY(0); }
}
.feedback-header {
    display: flex;
    justify-content: space-between;
    align-items: center;
    padding: 1rem 1.2rem;
    border-bottom: 1px solid var(--border);
}
.feedback-header h3 {
    margin: 0;
    font-size: 1rem;
    color: var(--text-primary);
}
.feedback-close {
    background: none;
    border: none;
    color: var(--text-muted);
    cursor: pointer;
    font-size: 1.2rem;
    padding: 0;
}
.feedback-form {
    padding: 1rem 1.2rem;
}
.feedback-field {
    margin-bottom: 0.8rem;
}
.feedback-field label {
    display: block;
    font-size: 0.8rem;
    color: var(--text-secondary);
    margin-bottom: 0.3rem;
    font-weight: 600;
}
.feedback-type-btns {
    display: flex;
    gap: 0.5rem;
}
.feedback-type-label {
    display: flex !important;
    align-items: center;
    gap: 0.25rem;
    font-size: 0.8rem !important;
    color: var(--text-primary) !important;
    cursor: pointer;
    padding: 0.3rem 0.6rem;
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    transition: all 0.2s;
}
.feedback-type-label:has(input:checked) {
    border-color: var(--accent-blue);
    background: rgba(59,130,246,0.1);
}
.feedback-type-label input {
    display: none;
}
.feedback-form textarea,
.feedback-form input[type="email"] {
    width: 100%;
    padding: 0.5rem 0.7rem;
    background: var(--background);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    color: var(--text-primary);
    font-size: 0.85rem;
    font-family: inherit;
    resize: vertical;
    box-sizing: border-box;
}
.feedback-form textarea:focus,
.feedback-form input[type="email"]:focus {
    outline: none;
    border-color: var(--accent-blue);
}
.feedback-submit {
    width: 100%;
    background: var(--accent-blue);
    color: white;
    border: none;
    padding: 0.6rem;
    border-radius: 0.5rem;
    cursor: pointer;
    font-weight: 600;
    font-size: 0.9rem;
    transition: background 0.2s;
}
.feedback-submit:hover {
    background: var(--accent-purple);
}
.feedback-success {
    padding: 2rem;
    text-align: center;
    color: var(--text-secondary);
}

/* Pagination */
.pagination {
    display: flex;
    justify-content: center;
    gap: 0.5rem;
    margin: 3rem 0;
}

.pagination a,
.pagination span {
    padding: 0.75rem 1rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-secondary);
    transition: all 0.2s ease;
}

.pagination a:hover {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

.pagination span.current {
    background: var(--accent-blue);
    border-color: var(--accent-blue);
    color: white;
}

/* Responsive */
@media (max-width: 768px) {
    .header-inner {
        padding: 1rem;
    }

    .nav-links {
        display: none;
        position: absolute;
        top: 4rem;
        left: 0;
        right: 0;
        background: var(--bg-secondary);
        flex-direction: column;
        gap: 0;
        border-bottom: 1px solid var(--border);
        border-radius: 0;
    }

    .nav-links.active {
        display: flex;
    }

    .nav-links li {
        padding: 1rem;
        border-bottom: 1px solid var(--border);
    }

    .nav-toggle {
        display: flex;
    }

    .hero h1 {
        font-size: 2rem;
    }

    .hero .tagline {
        font-size: 1rem;
    }

    .article-grid {
        grid-template-columns: 1fr;
        padding: 0 1rem 2rem 1rem;
    }

    .entity-grid {
        grid-template-columns: 1fr;
        padding: 0 1rem 2rem 1rem;
    }

    .article-page {
        padding: 1rem;
    }

    .article-content h1 {
        font-size: 1.75rem;
    }

    .article-content h2 {
        font-size: 1.5rem;
    }

    .article-meta-bar {
        flex-direction: column;
        align-items: flex-start;
    }

    .search-container {
        padding: 0 1rem;
    }

    .filter-buttons {
        overflow-x: auto;
        padding-bottom: 1rem;
    }

    .share-bar {
        flex-direction: column;
        align-items: flex-start;
    }

    .sibling-pills {
        overflow-x: auto;
        padding-bottom: 0.5rem;
    }

    .entity-hero-content {
        flex-direction: column;
        text-align: center;
    }

    .entity-hero-title {
        font-size: 2rem;
    }
}

@media (max-width: 480px) {
    .header-inner {
        padding: 0.75rem;
    }

    .site-logo {
        font-size: 1.2rem;
    }

    .hero h1 {
        font-size: 1.5rem;
    }

    .hero-stats {
        grid-template-columns: 1fr;
    }

    .article-grid {
        gap: 1rem;
    }

    .article-content {
        font-size: 1rem;
    }

    .article-content h1 {
        font-size: 1.5rem;
    }

    .article-content h2 {
        font-size: 1.25rem;
    }

    .article-content h3 {
        font-size: 1.1rem;
    }

    .card-title {
        font-size: 1rem;
    }

    .breadcrumb {
        font-size: 0.8rem;
    }

    .sibling-pill {
        padding: 0.5rem 1rem;
        font-size: 0.85rem;
    }

    .share-btn {
        padding: 0.6rem 1rem;
        font-size: 0.85rem;
    }
}

/* PHASE D1: Newsletter CTA */
.newsletter-cta {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2.5rem;
    text-align: center;
    margin: 3rem 0;
    max-width: 600px;
    margin-left: auto;
    margin-right: auto;
}

.newsletter-cta h3 {
    font-size: 1.5rem;
    margin-bottom: 0.5rem;
    color: var(--text-primary);
}

.newsletter-cta p {
    color: var(--text-secondary);
    margin-bottom: 1.5rem;
    font-size: 1rem;
}

.newsletter-cta form {
    display: flex;
    gap: 0.5rem;
    flex-direction: column;
}

.newsletter-cta input {
    padding: 0.75rem 1rem;
    background: var(--bg-primary);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-primary);
    font-size: 1rem;
}

.newsletter-cta input::placeholder {
    color: var(--text-muted);
}

.newsletter-cta button {
    padding: 0.75rem 1.5rem;
    background: var(--accent-blue);
    color: white;
    border: none;
    border-radius: 0.25rem;
    font-weight: 600;
    cursor: pointer;
    transition: background 0.2s ease;
}

.newsletter-cta button:hover {
    background: var(--accent-purple);
}

/* PHASE F1: Feedback bar */
.feedback-bar {
    display: flex;
    gap: 2rem;
    justify-content: center;
    padding: 2rem 0;
    border-top: 1px solid var(--border);
    margin-top: 3rem;
    flex-wrap: wrap;
}

.feedback-bar a {
    color: var(--text-secondary);
    font-weight: 500;
    transition: color 0.2s ease;
    display: inline-flex;
    align-items: center;
    gap: 0.5rem;
}

.feedback-bar a:hover {
    color: var(--accent-blue);
}

/* PHASE C1: Company view toggles */
.view-toggle-buttons {
    display: flex;
    gap: 1rem;
    justify-content: center;
    margin: 2rem 0;
    flex-wrap: wrap;
}

.view-toggle-btn {
    padding: 0.75rem 1.5rem;
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.25rem;
    color: var(--text-secondary);
    font-weight: 500;
    cursor: pointer;
    transition: all 0.2s ease;
}

.view-toggle-btn.active {
    background: var(--accent-blue);
    color: white;
    border-color: var(--accent-blue);
}

.view-toggle-btn:hover {
    border-color: var(--accent-blue);
    color: var(--text-primary);
}

.entity-view {
    display: none;
}

.entity-view.active {
    display: block;
}

.sector-group {
    margin-bottom: 3rem;
}

.sector-group h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
    padding-bottom: 0.5rem;
    border-bottom: 1px solid var(--border);
}

.country-group {
    margin-bottom: 3rem;
}

.country-group h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
    padding-bottom: 0.5rem;
    border-bottom: 1px solid var(--border);
}

/* Related section for companies */
.related-section {
    background: var(--bg-card);
    border: 1px solid var(--border);
    border-radius: 0.5rem;
    padding: 2rem;
    margin: 3rem 0;
}

.related-section h3 {
    font-size: 1.25rem;
    margin-bottom: 1.5rem;
    color: var(--text-primary);
}

.related-links {
    display: flex;
    flex-direction: column;
    gap: 1rem;
}

.related-links a {
    padding: 1rem;
    background: var(--bg-primary);
    border-radius: 0.25rem;
    color: var(--accent-blue);
    font-weight: 500;
    transition: all 0.2s ease;
    display: flex;
    justify-content: space-between;
    align-items: center;
}

.related-links a:hover {
    background: var(--bg-card-hover);
    color: var(--accent-purple);
}

@media (max-width: 768px) {
    .newsletter-cta {
        padding: 1.5rem;
    }

    .feedback-bar {
        gap: 1rem;
    }

    .view-toggle-buttons {
        gap: 0.5rem;
    }

    .view-toggle-btn {
        padding: 0.6rem 1rem;
        font-size: 0.9rem;
    }
}
</style>
    <!-- GA4 Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-S9Z93KZ2Z2"></script>
    <script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments);}gtag('js',new Date());gtag('config','G-S9Z93KZ2Z2');</script>
</head>
<body>
    <header class="site-header">
        <div class="header-inner">
            <a href="/" class="site-logo">
                <div class="logo-mark">30</div>
                <div class="logo-text">
                    <div class="logo-text-main">2030</div>
                    <div class="logo-text-sub">Report</div>
                </div>
            </a>
            <nav class="nav-links">
                <li><a href="/">Dashboard</a></li>
                <li><a href="/browse/countries.html">Countries</a></li>
                <li><a href="/browse/companies.html">Companies</a></li>
                <li><a href="/browse/sectors.html">Sectors</a></li>
                <li><a href="/government.html">Government</a></li>
                <li><a href="/search.html">Search</a></li>
                <li><a href="/about.html">About</a></li>
            </nav>
            <button class="nav-toggle" onclick="toggleNav()">
                <span></span>
                <span></span>
                <span></span>
            </button>
        </div>
    </header>

    <main class="article-page">
        <div class="breadcrumb">
            <a href="/">Home</a><span>/</span><a href="/browse/companies.html">Companies</a><span>/</span><a href="/browse/companies/sun-pharma.html">Sun Pharma</a><span>/</span><span>Analyst</span>
        </div>

        <article class="article-header">
            <div class="article-meta-bar">
                <div class="article-category">
                    <span class="card-badge badge-companies">üè¢ Companies</span>
                    <span class="card-audience">üë§ Analyst</span>
                </div>
                <div class="read-time">‚è±Ô∏è 18 min read</div>
            </div>

            <div class="entity-name-display">üè¢ Sun Pharma</div>
            
        <div class="share-bar">
            <span class="share-bar-label">Share:</span>
            <button class="share-btn" onclick="copyLink(event)">üìã Copy Link</button>
            <button class="share-btn" onclick="shareOnTwitter()">ùïè Twitter</button>
            <button class="share-btn" onclick="shareOnLinkedIn()">üíº LinkedIn</button>
            <button class="share-btn" onclick="shareOnFacebook()">üìò Facebook</button>
            <button class="share-btn" onclick="shareOnWhatsApp()">üí¨ WhatsApp</button>
            <button class="share-btn" onclick="shareViaEmail()">‚úâÔ∏è Email</button>
        </div>
        
            
        <div class="sibling-nav">
            <div class="sibling-nav-label">All Perspectives:</div>
            <div class="sibling-pills">
                <div class="sibling-pill "><a href="/articles/companies-india-sun-pharma-sunpharma-ceo.html">CEO</a></div><div class="sibling-pill "><a href="/articles/companies-india-sun-pharma-sunpharma-employee.html">Employee</a></div><div class="sibling-pill active"><a href="/articles/companies-india-sun-pharma-sunpharma-investor.html">Analyst</a></div>
            </div>
        </div>
        

            <div class="article-content">
                <h1>ENTITY: SUN PHARMACEUTICAL INDUSTRIES LIMITED</h1>
<h2>A Macro Intelligence Memo | June 2030 | Institutional Investor Edition</h2>
<p><strong>From:</strong> The 2030 Report<br />
<strong>Date:</strong> June 30, 2030<br />
<strong>Re:</strong> Sun Pharma: Generic Pharma Resilience, Export Economics, and AI Drug Discovery Optionality Through Market Volatility</p>
<hr />
<h2>SUMMARY: THE BEAR CASE vs. THE BULL CASE</h2>
<p><strong>THE BEAR CASE:</strong> INR strengthens unexpectedly. Pharma pricing pressure emerges in USA/Europe. AI drug programs fail to progress to Phase III. Margin compression to 19-20%. Stock declines to ‚Çπ870 (-5.4% downside). Growth slows to 3-4% CAGR.</p>
<p><strong>THE BULL CASE (Likely):</strong> AI drugs advance to Phase III successfully. Margin expansion to 23-24% through operating leverage. Revenue growth accelerates to 8-10% CAGR. Stock reaches ‚Çπ1,298 (+41% upside). Dividend growth resumes at 8-10% annually.</p>
<hr />
<h2>EXECUTIVE SUMMARY</h2>
<p>Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA), India's largest generic pharmaceutical manufacturer with ‚Çπ47.8 billion (USD 5.8 billion) in annual revenue, has demonstrated exceptional resilience through the 2028-2030 global market volatility period. Despite the Indian equity market declining 34% (Nifty-50 index), Sun Pharma has appreciated 8% (including dividends), validating the investment thesis that pharmaceutical consumption is fundamentally resistant to economic downturns.</p>
<p>The company's outperformance reflects three structural advantages: (1) essential medicine demand resilience‚Äîbasic pharmaceutical consumption remains stable despite consumer discretionary spending collapse, (2) export economics advantage‚Äîthe 18% Indian rupee depreciation (FY2028-2030) expanded export-derived margins for the company's 68% export-dependent revenue base, and (3) AI-driven drug discovery‚Äîearly investment in machine learning-based drug development is yielding pipeline advancement velocity superior to industry peers.</p>
<p>At ‚Çπ920 per share (June 2030), Sun Pharma offers institutional investors pharmaceutical sector exposure with unique structural advantages in AI-driven drug discovery, currency hedging benefit, and demand-resilient characteristics during periods of economic uncertainty.</p>
<hr />
<h2>SECTION 1: SUN PHARMA'S BUSINESS MODEL AND REVENUE STRUCTURE</h2>
<h3>Company Overview and Market Position</h3>
<p><strong>Corporate Profile:</strong><br />
- Founded: 1983 (47 years of operational history)<br />
- Headquarters: Mumbai, India<br />
- CEO: Dilip Shanghvi (founder, ~33% ownership stake)<br />
- Market capitalization: ‚Çπ6.24 trillion (USD 75.8 billion, June 2030)<br />
- Employees: ~24,000 globally</p>
<p><strong>Market Position in Indian Pharma:</strong><br />
- India's largest generic pharmaceutical manufacturer by revenue<br />
- Global ranking: Top 5 generic pharma companies globally<br />
- Revenue: ‚Çπ47.8B (FY2030 estimate)<br />
- EBITDA: ‚Çπ10.4B (21.8% margin)</p>
<h3>Revenue Breakdown and Geographic Diversification</h3>
<p><strong>Geographic Revenue Mix (FY2030 estimated):</strong></p>
<table>
<thead>
<tr>
<th>Region</th>
<th>Revenue</th>
<th>% of Total</th>
<th>Growth Rate</th>
<th>Key Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domestic India</td>
<td>‚Çπ15.3B</td>
<td>32%</td>
<td>+3-4%</td>
<td>Regulated price; stable</td>
</tr>
<tr>
<td>USA/North America</td>
<td>‚Çπ18.2B</td>
<td>38%</td>
<td>+6-8%</td>
<td>Largest geographic segment</td>
</tr>
<tr>
<td>Europe</td>
<td>‚Çπ7.4B</td>
<td>15%</td>
<td>+5-7%</td>
<td>Generic/branded mix</td>
</tr>
<tr>
<td>Emerging Markets</td>
<td>‚Çπ4.6B</td>
<td>10%</td>
<td>+8-12%</td>
<td>High growth but volatile</td>
</tr>
<tr>
<td>Japan/Others</td>
<td>‚Çπ2.3B</td>
<td>5%</td>
<td>+2-4%</td>
<td>Specialty pharma</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>‚Çπ47.8B</strong></td>
<td><strong>100%</strong></td>
<td><strong>+5.1%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>Key Insight:</strong> 68% of revenue is from outside India (export-dependent), providing currency exposure benefit/risk depending on rupee movements.</p>
<h3>Product Portfolio Composition</h3>
<p><strong>Therapeutic Category Mix (FY2030 estimated):</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Revenue</th>
<th>% of Total</th>
<th>Growth</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmology</td>
<td>‚Çπ11.4B</td>
<td>23.9%</td>
<td>+7.2%</td>
<td>Specialty; high-margin</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>‚Çπ8.2B</td>
<td>17.2%</td>
<td>+4.8%</td>
<td>Generic; commodity</td>
</tr>
<tr>
<td>Cardiology</td>
<td>‚Çπ7.1B</td>
<td>14.9%</td>
<td>+5.1%</td>
<td>Mix of generic/branded</td>
</tr>
<tr>
<td>Oncology</td>
<td>‚Çπ5.6B</td>
<td>11.7%</td>
<td>+9.3%</td>
<td>High-value; growing</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>‚Çπ4.3B</td>
<td>9.0%</td>
<td>+2.1%</td>
<td>Commodity; declining</td>
</tr>
<tr>
<td>CNS/Psychiatry</td>
<td>‚Çπ3.8B</td>
<td>7.9%</td>
<td>+12.4%</td>
<td>Growing; depression/anxiety demand</td>
</tr>
<tr>
<td>Other</td>
<td>‚Çπ6.4B</td>
<td>13.4%</td>
<td>+4.2%</td>
<td>Diversified</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>‚Çπ47.8B</strong></td>
<td><strong>100%</strong></td>
<td><strong>+5.1%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>Strategic insight:</strong> Ophthalmology (23.9% of revenue) is highest-margin category, providing stable earnings base. Oncology (11.7%, growing 9.3%) is high-value growth driver.</p>
<hr />
<h2>SECTION 2: PHARMACEUTICAL SECTOR RESILIENCE DURING 2028-2030 CRISIS</h2>
<h3>The Economic Crisis Context (2028-2030)</h3>
<p><strong>Macroeconomic Conditions:</strong><br />
- Global GDP growth: +0.8% (2029), +1.2% (2030) ‚Äî severe deceleration<br />
- Indian GDP growth: +3.2% (2029), +3.8% (2030) ‚Äî below historical trend<br />
- Consumer spending: Contracted 8-12% across major developed markets (2028-2029)<br />
- Equity markets: Significant volatility; major indices down 25-35% from peaks</p>
<h3>Pharmaceutical Demand Resilience</h3>
<p>Unlike discretionary consumer goods, pharmaceutical consumption remained resilient:</p>
<p><strong>Volume Trends by Therapeutic Category (FY2028-FY2030):</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Volume Growth</th>
<th>Reason</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain relief/Cold OTC</td>
<td>+0.5% to +2.1%</td>
<td>Essential; self-treating behavior</td>
<td>Stable; non-discretionary</td>
</tr>
<tr>
<td>Chronic disease (diabetes, hypertension)</td>
<td>+3.2% to +5.1%</td>
<td>Medical necessity; continued treatment</td>
<td>Stable; government-supported</td>
</tr>
<tr>
<td>Antibiotic/infection treatment</td>
<td>+1.0% to +2.0%</td>
<td>Essential; non-deferrable</td>
<td>Stable</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>+1.8% to +3.2%</td>
<td>Stress-induced consumption</td>
<td>Growing (stress-driven)</td>
</tr>
<tr>
<td>CNS/Psychiatry</td>
<td>+8.0% to +12.4%</td>
<td>Depression/anxiety increased</td>
<td>Growing (crisis-driven)</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>+2.0% to +4.2%</td>
<td>Medical need; non-deferrable</td>
<td>Stable</td>
</tr>
<tr>
<td>Oncology</td>
<td>+6.0% to +9.3%</td>
<td>Medical necessity; high urgency</td>
<td>Growing (treatment continues)</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>+2.0% to +4.8%</td>
<td>Medical necessity; continued treatment</td>
<td>Stable</td>
</tr>
</tbody>
</table>
<p><strong>Key finding:</strong> Pharmaceutical consumption grew 3-6% (inflation-adjusted) across categories despite 8-12% consumer discretionary spending contraction. This 300-400 basis point resilience premium demonstrates pharmaceutical demand inelasticity.</p>
<h3>Pricing Power Maintenance</h3>
<p>Pharmaceutical companies (including Sun Pharma) maintained pricing power despite volume growth:</p>
<p><strong>Pricing Dynamics by Category (FY2028-FY2030):</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Price Growth</th>
<th>Reason</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulated medicines (India)</td>
<td>+2-3%</td>
<td>Government-controlled; limited flexibility</td>
<td>Stable margins</td>
</tr>
<tr>
<td>OTC medicines</td>
<td>+3-5%</td>
<td>Competing on efficacy; price secondary</td>
<td>Strong margins</td>
</tr>
<tr>
<td>Prescription medicines</td>
<td>+4-6%</td>
<td>Doctor-recommended; brand value</td>
<td>Strong margins</td>
</tr>
<tr>
<td>Generics (USA)</td>
<td>+1-2%</td>
<td>Competitive; price-sensitive</td>
<td>Compressed margins</td>
</tr>
</tbody>
</table>
<p><strong>Result:</strong> Blended price growth of +2.8% offset volume growth challenges; gross margins remained stable at 65-68% despite production scaling challenges.</p>
<p><strong>Sun Pharma Operating Margin:</strong><br />
- FY2028: 21.4%<br />
- FY2029: 21.6%<br />
- FY2030E: 21.8%</p>
<p>Operating margins actually improved slightly despite crisis, reflecting underlying pharmaceutical business resilience and operational discipline.</p>
<hr />
<h2>SECTION 3: CURRENCY ECONOMICS AND EXPORT ADVANTAGE</h2>
<h3>The Rupee Depreciation Benefit (FY2028-FY2030)</h3>
<p><strong>Currency Movement:</strong><br />
- FY2028 average rate: ‚Çπ82/USD<br />
- FY2029 average rate: ‚Çπ88/USD<br />
- FY2030 estimated average: ‚Çπ96.8/USD<br />
- Total depreciation: 18% over 24 months</p>
<p><strong>Impact on Export-Dependent Companies:</strong></p>
<p>Sun Pharma's revenue structure (68% exports):<br />
- Export revenue in rupees: Grows in USD terms due to depreciation<br />
- Cost structure in rupees: Benefits from currency depreciation (input costs stable in INR)<br />
- Net effect: Export margins expand due to currency arbitrage</p>
<p><strong>Financial Impact Model:</strong></p>
<p><strong>FY2028 Baseline (Pre-depreciation):</strong><br />
- Export revenue (USA, Europe): ‚Çπ31.8B<br />
- Dollar equivalent (at ‚Çπ82/USD): USD 387M<br />
- Cost structure (in INR): ‚Çπ25.4B<br />
- Margin: ‚Çπ6.4B = 20.1%</p>
<p><strong>FY2030 Post-depreciation:</strong><br />
- Export volume (unchanged): ‚Çπ31.8B (same rupee volume, similar dollar units)<br />
- But at ‚Çπ96.8/USD: Still USD 328M in dollar terms (lower)<br />
- However, cost structure (also in INR): ‚Çπ25.4B (unchanged, but now worth more USD)<br />
- Net effect: Real margins expand due to cost structure remaining INR-denominated while revenue partially USD-denominated</p>
<p><strong>Quantification:</strong><br />
- Currency benefit: ~8-12% margin expansion on export segment (68% of revenue)<br />
- Blended company margin benefit: ~5.4-8.2% from currency arbitrage<br />
- This benefit partially offset by reduced USD revenue value</p>
<p><strong>Strategic Implication:</strong> Rupee depreciation was net positive for Sun Pharma despite reducing dollar-value of USD revenues, because cost structure remained INR-denominated while a portion of revenue was USD-locked.</p>
<h3>Competitive Advantage vs. Peers</h3>
<p>Sun Pharma benefited disproportionately from rupee depreciation compared to:<br />
- <strong>Domestic pharma peers:</strong> Companies with higher domestic revenue (‚Çπ) benefited less<br />
- <strong>Global pharma peers:</strong> USD-based companies faced no currency benefit<br />
- <strong>Indian IT services companies:</strong> Export-heavy but with higher labor costs (reduced benefit)</p>
<p>Sun Pharma's 68% export revenue and manufacturing-heavy cost structure made it a prime beneficiary of INR depreciation.</p>
<hr />
<h2>SECTION 4: AI-DRIVEN DRUG DISCOVERY AND PIPELINE OPTIONALITY</h2>
<h3>Early AI Investment (2025-2027)</h3>
<p>Sun Pharma was an early investor in AI-driven drug discovery, beginning initiatives in 2025:</p>
<p><strong>AI Drug Discovery Program:</strong><br />
- Founded: 2025<br />
- Initial investment: ‚Çπ220 crore (USD 26M) in FY2025<br />
- Cumulative investment by FY2030: ‚Çπ420 crore (USD 51M)<br />
- Partnerships: Collaborations with AI biotech startups (Atomwise, others)<br />
- In-house capability: Built proprietary AI platform for molecule screening</p>
<p><strong>Investment Rationale:</strong><br />
- Traditional pharma R&amp;D: High cost (USD 1.5-2.0B per new drug), long timeline (10-12 years)<br />
- AI-enabled R&amp;D: Lower cost (USD 300-500M estimated), faster timeline (6-8 years)<br />
- Sun Pharma saw opportunity: Lower cost R&amp;D could generate higher returns and pipeline diversity</p>
<h3>AI Contribution to Pipeline (FY2030)</h3>
<p><strong>Pipeline Advancement Metrics:</strong></p>
<table>
<thead>
<tr>
<th>Metric</th>
<th>Sun Pharma</th>
<th>Industry Average</th>
<th>Sun Pharma Advantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI-driven molecules in pipeline</td>
<td>12-15</td>
<td>~3-5</td>
<td>250-300% higher</td>
</tr>
<tr>
<td>Time to Phase II (AI-discovered)</td>
<td>4.2 years</td>
<td>6.8 years</td>
<td>-38% faster</td>
</tr>
<tr>
<td>Cost to Phase II (AI-discovered)</td>
<td>USD 180M</td>
<td>USD 320M</td>
<td>-44% cheaper</td>
</tr>
<tr>
<td>Phase II advancement success rate</td>
<td>38%</td>
<td>28%</td>
<td>+10pp higher</td>
</tr>
</tbody>
</table>
<p><strong>Notable Pipeline Achievements (FY2030):</strong></p>
<table>
<thead>
<tr>
<th>Molecule</th>
<th>Indication</th>
<th>Status</th>
<th>Timeline</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUN-101</td>
<td>Ophthalmology (dry eye)</td>
<td>Phase II</td>
<td>2032-2033 approval target</td>
<td>Ophthalmology focus</td>
</tr>
<tr>
<td>SUN-102</td>
<td>Oncology (breast cancer)</td>
<td>Phase II</td>
<td>2033-2034 approval target</td>
<td>High-value indication</td>
</tr>
<tr>
<td>SUN-103</td>
<td>Gastroenterology (IBD)</td>
<td>Phase IIb</td>
<td>2034 approval target</td>
<td>AI-discovered via computational screening</td>
</tr>
</tbody>
</table>
<p><strong>Competitive Advantage:</strong><br />
- Sun Pharma's AI-driven discovery program is delivering pipeline advancement velocity superior to industry peers<br />
- By FY2030, ~12% of Sun Pharma's pipeline molecules originated from AI-driven discovery (vs. ~0-2% for peer group)<br />
- This positions Sun Pharma for 5-10 year competitive advantage in drug development productivity</p>
<h3>Valuation Impact of AI Drug Discovery</h3>
<p><strong>Pipeline Optionality Value:</strong></p>
<ul>
<li>Current approved drugs: Value reflected in existing revenue stream (‚Çπ47.8B)</li>
<li>Pipeline molecules (Phase II-IIb): Estimated value USD 5-8B in NPV terms</li>
<li>3 Phase II molecules: USD 1-2B NPV each (if 30% probability of approval)</li>
<li>Market size: USD 8-12B for breast cancer oncology indication</li>
<li>Peak sales potential: USD 1.2-1.8B per drug</li>
<li>Probability-weighted NPV: USD 5-8B total</li>
</ul>
<p><strong>Implied Enterprise Value Bridge:</strong><br />
- Current enterprise value: ‚Çπ6.24T (June 2030)<br />
- Derived from: Existing drug portfolio value<br />
- Additional upside from: AI-driven pipeline (if successful)<br />
- Bull case valuation: ‚Çπ7.2-8.4T (if 1-2 AI molecules reach approval)<br />
- Base case valuation: ‚Çπ6.2-7.0T (1 AI molecule reaches approval)<br />
- Bear case valuation: ‚Çπ5.2-6.0T (no AI molecules succeed)</p>
<hr />
<h2>SECTION 5: FINANCIAL ANALYSIS AND VALUATION</h2>
<h3>Financial Summary (FY2030)</h3>
<table>
<thead>
<tr>
<th>Metric</th>
<th>FY2028</th>
<th>FY2030E</th>
<th>CAGR</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>‚Çπ44.2B</td>
<td>‚Çπ47.8B</td>
<td>+4.0%</td>
<td>Modest growth</td>
</tr>
<tr>
<td>EBITDA</td>
<td>‚Çπ9.1B</td>
<td>‚Çπ10.4B</td>
<td>+7.2%</td>
<td>Margin expansion</td>
</tr>
<tr>
<td>EBITDA Margin</td>
<td>20.6%</td>
<td>21.8%</td>
<td>+120bps</td>
<td>Improving</td>
</tr>
<tr>
<td>Net Income</td>
<td>‚Çπ6.2B</td>
<td>‚Çπ7.4B</td>
<td>+9.3%</td>
<td>Strong growth</td>
</tr>
<tr>
<td>Net Margin</td>
<td>14.0%</td>
<td>15.5%</td>
<td>+150bps</td>
<td>Improving</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>‚Çπ5.8B</td>
<td>‚Çπ6.9B</td>
<td>+9.1%</td>
<td>Strong</td>
</tr>
</tbody>
</table>
<h3>Valuation Metrics (June 2030)</h3>
<p><strong>Current Valuation:</strong><br />
- Stock price: ‚Çπ920/share<br />
- Market cap: ‚Çπ6.24T (USD 75.8B)<br />
- Shares outstanding: 678M</p>
<p><strong>Valuation Multiples:</strong><br />
- P/E ratio: 18.2x (FY2030 earnings estimate)<br />
- EV/EBITDA: 17.8x (enterprise value to EBITDA)<br />
- Price/Book: 8.2x (tangible book value per share)<br />
- PEG ratio (P/E to growth): 3.6x (P/E 18.2 / growth 5.1%)</p>
<p><strong>Valuation Comparables:</strong></p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Country</th>
<th>P/E (FY2030)</th>
<th>EV/EBITDA</th>
<th>Growth</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun Pharma</td>
<td>India</td>
<td>18.2x</td>
<td>17.8x</td>
<td>+5.1%</td>
<td>Generic + AI optionality</td>
</tr>
<tr>
<td>Cipla</td>
<td>India</td>
<td>16.4x</td>
<td>15.2x</td>
<td>+3.2%</td>
<td>Pure generic play</td>
</tr>
<tr>
<td>Lupin</td>
<td>India</td>
<td>15.8x</td>
<td>14.6x</td>
<td>+2.8%</td>
<td>Generic play</td>
</tr>
<tr>
<td>Teva Pharma</td>
<td>Israel</td>
<td>8.2x</td>
<td>6.4x</td>
<td>+1.2%</td>
<td>Mature generic; lower growth</td>
</tr>
<tr>
<td>Mylan/Viatris</td>
<td>USA</td>
<td>9.1x</td>
<td>7.8x</td>
<td>+0.8%</td>
<td>Mature; declining</td>
</tr>
</tbody>
</table>
<p><strong>Assessment:</strong> Sun Pharma trades at significant premium to peers (18.2x vs. peer average 11.1x), justified by: (1) 5.1% growth (vs. peer average 2.0%), (2) AI drug discovery optionality, (3) margin expansion dynamics, (4) export advantage from currency.</p>
<h3>DCF Valuation</h3>
<p><strong>Assumptions (FY2030-2035):</strong></p>
<table>
<thead>
<tr>
<th>Metric</th>
<th>Assumption</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue CAGR 2030-2035</td>
<td>6.2%</td>
<td>Modest pharma growth + AI pipeline contributions</td>
</tr>
<tr>
<td>EBITDA Margin 2035</td>
<td>23.2%</td>
<td>Gradual margin expansion from AI drug sales</td>
</tr>
<tr>
<td>Terminal Growth</td>
<td>2.8%</td>
<td>Inflation + modest real growth</td>
</tr>
<tr>
<td>WACC</td>
<td>8.2%</td>
<td>Higher than developed market pharma; India risk premium</td>
</tr>
<tr>
<td>Tax Rate</td>
<td>21%</td>
<td>India corporate tax rate</td>
</tr>
</tbody>
</table>
<p><strong>DCF Valuation Output:</strong></p>
<table>
<thead>
<tr>
<th>Scenario</th>
<th>2035 Value</th>
<th>Terminal Value</th>
<th>Enterprise Value</th>
<th>Per Share</th>
<th>Upside/(Downside)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Base</strong></td>
<td>‚Çπ10.2B EBITDA</td>
<td>‚Çπ86.4T</td>
<td>‚Çπ7.2T</td>
<td>‚Çπ1,060</td>
<td>+15.2%</td>
</tr>
<tr>
<td>Bull</td>
<td>‚Çπ11.8B EBITDA</td>
<td>‚Çπ104.2T</td>
<td>‚Çπ8.8T</td>
<td>‚Çπ1,298</td>
<td>+41.1%</td>
</tr>
<tr>
<td>Bear</td>
<td>‚Çπ8.8B EBITDA</td>
<td>‚Çπ71.2T</td>
<td>‚Çπ5.9T</td>
<td>‚Çπ870</td>
<td>-5.4%</td>
</tr>
</tbody>
</table>
<hr />
<h2>SECTION 6: RISK ASSESSMENT AND SENSITIVITY</h2>
<h3>Key Risks to Investment Thesis</h3>
<p><strong>1. Generic Pharma Price Compression Risk (Medium probability: 35%)</strong><br />
- Continued price competition in USA generic market (largest market, 38% of revenue)<br />
- Risk: Gross margins compress 50-150 bps if price competition intensifies<br />
- Mitigation: Diversification into specialty/branded pharma (ophthalmology, oncology); AI optionality<br />
- Impact if realized: Valuation downside of 10-15%</p>
<p><strong>2. AI Drug Discovery Execution Risk (Medium probability: 40%)</strong><br />
- Pipeline molecules may fail to achieve approval targets<br />
- Risk: AI molecules in Phase II may fail advancement<br />
- Mitigation: Diversified AI pipeline (3+ molecules); partnership with external AI biotech<br />
- Impact if realized: Valuation downside of 5-10% if all AI drugs fail</p>
<p><strong>3. Currency Volatility Risk (Medium probability: 35%)</strong><br />
- INR could strengthen unexpectedly, reducing export margin benefit<br />
- Risk: INR appreciation of 10% would compress export margins 5-7%<br />
- Mitigation: Hedging program; diversification across currencies<br />
- Impact if realized: Valuation downside of 8-12%</p>
<p><strong>4. Regulatory Risk in Key Markets (Low probability: 20%)</strong><br />
- USA FDA pricing/approval pressure<br />
- European regulatory changes<br />
- Risk: Approval delays or pricing caps reducing revenues<br />
- Mitigation: Diversification across geographies; compliance excellence<br />
- Impact if realized: Valuation downside of 5-10%</p>
<h3>Sensitivity Analysis</h3>
<p><strong>Sensitivity to EBITDA Margin (FY2030E: 21.8%):</strong></p>
<table>
<thead>
<tr>
<th>EBITDA Margin</th>
<th>Per Share Value</th>
<th>vs. Base Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>20.8%</td>
<td>‚Çπ1,004</td>
<td>-5.3%</td>
</tr>
<tr>
<td>21.8% (base)</td>
<td>‚Çπ1,060</td>
<td>Base</td>
</tr>
<tr>
<td>22.8%</td>
<td>‚Çπ1,128</td>
<td>+6.4%</td>
</tr>
<tr>
<td>23.8%</td>
<td>‚Çπ1,198</td>
<td>+13.0%</td>
</tr>
</tbody>
</table>
<p><strong>Sensitivity to Revenue Growth Rate (FY2030-2035 CAGR):</strong></p>
<table>
<thead>
<tr>
<th>Revenue CAGR</th>
<th>Per Share Value</th>
<th>vs. Base Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2%</td>
<td>‚Çπ940</td>
<td>-11.3%</td>
</tr>
<tr>
<td>6.2% (base)</td>
<td>‚Çπ1,060</td>
<td>Base</td>
</tr>
<tr>
<td>8.2%</td>
<td>‚Çπ1,198</td>
<td>+13.0%</td>
</tr>
<tr>
<td>10.2%</td>
<td>‚Çπ1,348</td>
<td>+27.2%</td>
</tr>
</tbody>
</table>
<hr />
<h2>THE DIVERGENCE: BEAR vs. BULL INVESTMENT OUTCOMES (2030-2035)</h2>
<table>
<thead>
<tr>
<th>Metric</th>
<th>Bear Case (20%)</th>
<th>Base Case (55%)</th>
<th>Bull Case (25%)</th>
<th>Key Divergence Driver</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue 2035 (‚ÇπB)</strong></td>
<td>56-58B</td>
<td>65-70B</td>
<td>75-80B</td>
<td>AI drug success and export growth</td>
</tr>
<tr>
<td><strong>EBITDA Margin 2035</strong></td>
<td>19-20%</td>
<td>22-23%</td>
<td>23-24%</td>
<td>Operating leverage and pricing power</td>
</tr>
<tr>
<td><strong>AI Drug Pipeline Success</strong></td>
<td>Failure</td>
<td>1-2 drugs approved</td>
<td>2-3 drugs approved</td>
<td>R&amp;D execution and clinical trial success</td>
</tr>
<tr>
<td><strong>Stock Price 2035</strong></td>
<td>‚Çπ870</td>
<td>‚Çπ1,100-1,200</td>
<td>‚Çπ1,450</td>
<td>Earnings growth and multiple expansion</td>
</tr>
<tr>
<td><strong>Dividend Per Share 2035</strong></td>
<td>‚Çπ28-30</td>
<td>‚Çπ38-42</td>
<td>‚Çπ50-55</td>
<td>Earnings growth and payout policy</td>
</tr>
<tr>
<td><strong>Upside/Downside from Current</strong></td>
<td>-5.4%</td>
<td>+15-30%</td>
<td>+41-58%</td>
<td>AI pipeline execution probability</td>
</tr>
</tbody>
</table>
<h3>THE BULL CASE ALTERNATIVE: AI Drug Success and Margin Expansion</h3>
<p><strong>Investor Implications (if executed):</strong><br />
- AI drug programs advance successfully to Phase III/approval by 2033-2035<br />
- Each approved drug generates ‚Çπ2-4B annual revenue peak with 50%+ gross margins<br />
- Export revenue growth accelerates to 8-10% annually as generic pharma demand stabilizes<br />
- EBITDA margins expand to 23-24% through operating leverage<br />
- Dividend growth accelerates to 8-10% annually<br />
- Stock price target ‚Çπ1,450/share (+57% upside by 2035)</p>
<p><strong>What would trigger bull case:</strong> Phase II advancement announcements for SUN-101, SUN-102 molecules, export volume growth maintaining 8%+ CAGR, EBITDA margin expansion above 22%, dividend growth reaching 8-10% annually, successful AI drug approval by 2034-2035.</p>
<p>Probability: 25% (market assigns moderate probability to AI drug success given early-stage nature)</p>
<h2>SECTION 7: INVESTMENT THESIS AND RECOMMENDATION</h2>
<h3>Investment Highlights</h3>
<p><strong>1. Pharmaceutical Demand Resilience</strong><br />
- Consumption proved resilient during 2028-2030 economic crisis<br />
- Sun Pharma demonstrated margin maintenance despite volume dynamics<br />
- Validates thesis that pharma is defensive investment in downturns</p>
<p><strong>2. Export Economics Advantage</strong><br />
- 68% revenue from exports provides currency hedging benefit<br />
- INR depreciation FY2028-2030 expanded export margins 5-8%<br />
- Provides structural advantage over domestic-focused peers</p>
<p><strong>3. AI Drug Discovery Optionality</strong><br />
- Early investment in AI-driven R&amp;D positioning Sun Pharma for competitive advantage<br />
- 3 molecules in Phase II/IIb with USD 5-8B NPV potential<br />
- Pipeline advancement velocity superior to industry peers</p>
<p><strong>4. Valuation Attractiveness</strong><br />
- P/E of 18.2x justified by 5.1% growth + AI optionality + margin expansion<br />
- DCF fair value ‚Çπ1,060 (15.2% upside from current ‚Çπ920)<br />
- Bull case valuation ‚Çπ1,298 (41.1% upside if AI drugs succeed + margins expand)</p>
<h3>Investment Recommendation</h3>
<p><strong>BEAR CASE RECOMMENDATION (20% probability - CAUTIOUS):</strong><br />
INR strengthens unexpectedly. Pharma pricing pressure intensifies. AI programs stall. Margin compresses to 19-20%. Stock declines to ‚Çπ870 (-5.4%). Growth slows to 3-4% CAGR. Avoid on currency strength signals; reduce on AI pipeline delays.</p>
<p><strong>BASE CASE RECOMMENDATION (55% probability - OVERWEIGHT):</strong><br />
Pharmaceutical demand remains resilient. Export revenue grows 6-7% annually. EBITDA margins stabilize at 22-23%. AI drug programs advance. Stock targets ‚Çπ1,060-1,100 (+15-20% upside). Overweight for defensive pharma exposure.</p>
<p><strong>BULL CASE CONSIDERATION (25% probability - OVERWEIGHT WITH CONVICTION):</strong><br />
AI drugs advance successfully to Phase III. Margin expansion to 23-24%. Revenue growth accelerates to 8-10% CAGR. Stock reaches ‚Çπ1,298-1,450 (+41-57% upside). Suitable for growth-oriented pharma investors.</p>
<p><strong>Overall Rating: OVERWEIGHT</strong></p>
<p><strong>Current Price:</strong> ‚Çπ920/share<br />
<strong>Fair Value (Base Case):</strong> ‚Çπ1,060/share (+15.2% upside)<br />
<strong>Bull Case Target:</strong> ‚Çπ1,298/share (+41.1% upside)<br />
<strong>Bear Case Target:</strong> ‚Çπ870/share (-5.4% downside)</p>
<p><strong>Time Horizon:</strong> 3-5 years (AI pipeline maturation timeline)</p>
<p><strong>Position Sizing Recommendation:</strong><br />
- For growth-oriented investors: 3-4% of portfolio allocation<br />
- For income-oriented investors: 2-3% allocation (2.8% dividend yield maintained)<br />
- For crisis-hedge investors: 2-3% allocation (defensive pharma characteristics)</p>
<h3>Key Catalysts</h3>
<p><strong>Near-term (FY2031-2032):</strong><br />
- Phase II advancement announcements for SUN-101, SUN-102 molecules<br />
- Export volume growth as global pharma market normalizes<br />
- Margin expansion from operating leverage</p>
<p><strong>Medium-term (FY2032-2034):</strong><br />
- Potential approval of 1-2 AI-discovered drugs<br />
- Phase III data releases<br />
- Potential partnerships or licensing deals based on AI pipeline success</p>
<hr />
<h2>CONCLUSION</h2>
<p>Sun Pharmaceutical emerges from the 2028-2030 economic volatility period as a compellingly positioned pharmaceutical investment with three structural advantages: (1) demand resilience from essential medicine category, (2) export economics benefit from INR-denominated costs and USD-denominated revenues, and (3) AI-driven drug discovery optionality creating pipeline diversification and value creation potential.</p>
<p>At ‚Çπ920 per share (June 2030), the stock offers attractive risk-reward: (1) 15.2% upside to fair value on base case, (2) 41.1% upside if AI drugs succeed, (3) downside protection from pharma demand resilience and current valuation multiples.</p>
<p>For institutional investors seeking pharmaceutical sector exposure with unique structural advantages and optionality, Sun Pharma represents a differentiated investment opportunity.</p>
<hr />
<p><strong>THE 2030 REPORT | Pharmaceutical &amp; Healthcare Intelligence | June 2030 | Institutional Investor Edition</strong><br />
<strong>Classification: Confidential - Qualified Investor Only | Word Count: 3,524</strong></p>
<h2>REFERENCES &amp; DATA SOURCES</h2>
<ol>
<li>Sun Pharmaceutical Annual Report &amp; Form 20-F Filing, FY2029 (SEC &amp; NSE Filing)</li>
<li>Bloomberg Intelligence, "Sun Pharmaceutical: Enterprise Valuation &amp; Equity Research," Q2 2030</li>
<li>McKinsey Global Institute, "AI Impact on Corporate Valuations in India," March 2029</li>
<li>Reserve Bank of India (RBI), "Corporate Credit and Financial Stability Review," June 2030</li>
<li>Reuters India, "Indian Corporate Sector: Investor Returns and Market Trends," Q1 2030</li>
<li>Gartner, "Digital Transformation ROI and Investor Value Creation," 2030</li>
<li>World Bank India Report, "Corporate Sector Productivity and Growth," 2029</li>
<li>Sun Pharmaceutical Investor Relations, Q4 2029 Earnings Presentation &amp; Guidance</li>
<li>IMF Economic Outlook, "India Corporate Sector Growth Projections," April 2030</li>
<li>CRISIL, "Indian Corporate Sector Credit and Investment Outlook," FY2029</li>
<li>Credit Suisse, f"{company_name} Equity Research Report," Q2 2030</li>
<li>Goldman Sachs, "India Corporate Sector: Consensus Earnings Estimates," June 2030</li>
</ol>
<hr />
<h2>WHAT YOU SHOULD DO NOW</h2>
<p>The investment landscape described in this memo creates clear winners and losers. Here's how to position yourself:</p>
<p><strong>Immediate portfolio review:</strong> Evaluate your holdings against the bear case scenarios described above. Companies with high labor costs, low AI adoption, and reactive management are value traps, not value investments.</p>
<p><strong>AI transformation screening:</strong> For every company in your portfolio, answer three questions: (1) Has the CEO publicly committed to AI transformation with specific capital allocation? (2) Is the company investing 3%+ of revenue in AI capabilities? (3) Does the company have a credible plan for workforce transition? If the answer to all three is no, consider your exit timeline.</p>
<p><strong>Sector allocation:</strong> Overweight sectors where AI creates new value (healthcare AI, AI infrastructure, AI-enabled services). Underweight sectors where AI primarily destroys existing value without creating new revenue streams.</p>
<p><strong>Geographic diversification:</strong> Countries with proactive AI policies, strong education systems, and flexible labor markets will outperform. Evaluate your geographic exposure accordingly.</p>
<p><strong>Due diligence upgrade:</strong> Add AI readiness assessment to your standard due diligence process. Ask management teams specifically about their AI strategy, timeline, and capital commitment. Vague answers are a red flag.</p>
<p><em>Read more: Browse all <a href="/browse/countries.html">Investor-focused memos</a> across 34 countries and <a href="/browse/companies.html">141 companies</a> for company-specific and country-specific investment analysis.</em></p>
            </div>
        </article>

        <div style="margin-top: 3rem; padding-top: 2rem; border-top: 1px solid var(--border); text-align: center;"><a href="/browse/companies/sun-pharma.html" style="display: inline-block; padding: 1rem 2rem; background: var(--bg-card); border: 1px solid var(--border); border-radius: 0.5rem; color: var(--text-primary); font-weight: 600; transition: all 0.2s ease;">‚Üê All Sun Pharma Articles</a></div>
        
        <div class="more-in-category">
            <h3>More in Companies</h3>
            <div class="more-grid">
                
            <div class="more-card">
                <h4>ENTITY: APPLE CORPORATION</h4>
                <p>FROM: The 2030 Report, Technology & Market Analysis Division</p>
                <a href="/articles/companies-us-apple-apple-ceo.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: APPLE INC.</h4>
                <p>From: The 2030 Report Global Intelligence Division</p>
                <a href="/articles/companies-us-apple-apple-investor.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: APPLE INC.</h4>
                <p>---</p>
                <a href="/articles/companies-us-apple-apple-employee.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: THE HOME DEPOT INC.</h4>
                <p>FROM: The 2030 Report</p>
                <a href="/articles/companies-us-home-depot-home-depot-ceo.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>HOME DEPOT: WORKFORCE RESTRUCTURING IN HOUSING DOWNTURN</h4>
                <p>FROM: The 2030 Report</p>
                <a href="/articles/companies-us-home-depot-home-depot-employee.html">Read more ‚Üí</a>
            </div>
            
            <div class="more-card">
                <h4>ENTITY: Home Depot, Inc. | Housing Market Downturn and Structural Retail Transformation</h4>
                <p>FROM: The 2030 Report | Retail and Consumer Spending Analysis</p>
                <a href="/articles/companies-us-home-depot-home-depot-investor.html">Read more ‚Üí</a>
            </div>
            
            </div>
        </div>
        

        <!-- Feedback Widget -->
        <div class="feedback-widget" id="feedbackWidget">
            <button class="feedback-toggle" onclick="toggleFeedback()" aria-label="Report an issue or send feedback">
                üí¨ Feedback
            </button>
            <div class="feedback-panel" id="feedbackPanel">
                <div class="feedback-header">
                    <h3>Send Feedback</h3>
                    <button class="feedback-close" onclick="toggleFeedback()">‚úï</button>
                </div>
                <form class="feedback-form" id="feedbackForm" onsubmit="submitFeedback(event)">
                    <input type="hidden" name="page_url" id="feedbackPageUrl">
                    <div class="feedback-field">
                        <label>Type</label>
                        <div class="feedback-type-btns">
                            <label class="feedback-type-label"><input type="radio" name="type" value="Error" required> üêõ Error</label>
                            <label class="feedback-type-label"><input type="radio" name="type" value="Suggestion"> üí° Suggestion</label>
                            <label class="feedback-type-label"><input type="radio" name="type" value="Other"> üìù Other</label>
                        </div>
                    </div>
                    <div class="feedback-field">
                        <label for="feedbackMsg">Message</label>
                        <textarea id="feedbackMsg" name="message" rows="3" placeholder="Tell us what's wrong or how we can improve..." required></textarea>
                    </div>
                    <div class="feedback-field">
                        <label for="feedbackEmail">Your Email (optional)</label>
                        <input type="email" id="feedbackEmail" name="email" placeholder="your@email.com">
                    </div>
                    <button type="submit" class="feedback-submit">Send Feedback</button>
                </form>
                <div class="feedback-success" id="feedbackSuccess" style="display:none;">
                    <div style="font-size:2rem;">‚úÖ</div>
                    <p>Thank you! Your email client will open with the feedback.</p>
                </div>
            </div>
        </div>

    </main>

    <footer class="site-footer">
        <div class="footer-content">
            <div class="footer-disclaimer">
                <strong>Disclaimer:</strong> This report provides forecasts and analysis of AI disruption trends. Predictions are based on current data and expert analysis but are subject to change. Use this information for informational purposes only.
            </div>
            <div class="footer-links">
                <a href="/">Home</a>
                <a href="/browse/countries.html">Countries</a>
                <a href="/browse/companies.html">Companies</a>
                <a href="/browse/sectors.html">Sectors</a>
                <a href="/government.html">Government</a>
                <a href="/press.html">Press</a>
                <a href="/about.html">About</a>
            </div>
            <div style="color: var(--text-muted); font-size: 0.85rem; margin-top: 1rem;">
                &copy; 2030 Intelligence Report. All rights reserved.
            </div>
        </div>
    </footer>

    <button class="back-to-top" onclick="scrollToTop()" title="Back to top">‚Üë</button>

    <script>
        function toggleNav() {
            const navLinks = document.querySelector('.nav-links');
            navLinks.classList.toggle('active');
        }
        // Highlight active nav item
        document.querySelectorAll('.nav-links a').forEach(link => {
            const href = link.getAttribute('href');
            const path = window.location.pathname;
            if (href === '/' && path === '/') link.classList.add('nav-active');
            else if (href !== '/' && path.startsWith(href.replace('.html', ''))) link.classList.add('nav-active');
        });

        function scrollToTop() {
            window.scrollTo({ top: 0, behavior: 'smooth' });
        }

        function copyLink(e) {
            const url = window.location.href;
            const btn = e.currentTarget;
            navigator.clipboard.writeText(url).then(() => {
                const originalText = btn.innerText;
                btn.innerText = '‚úì Copied!';
                btn.classList.add('copied');
                setTimeout(() => {
                    btn.innerText = originalText;
                    btn.classList.remove('copied');
                }, 2000);
            });
        }

        const pageTitle = document.title.split(' - ')[0];

        function shareOnTwitter() {
            const url = window.location.href;
            const text = encodeURIComponent(pageTitle + ' ‚Äî ' + url);
            window.open(`https://twitter.com/intent/tweet?text=${text}`, '_blank');
        }

        function shareOnLinkedIn() {
            const url = window.location.href;
            window.open(`https://www.linkedin.com/sharing/share-offsite/?url=${encodeURIComponent(url)}`, '_blank');
        }

        function shareOnFacebook() {
            const url = window.location.href;
            window.open(`https://www.facebook.com/sharer/sharer.php?u=${encodeURIComponent(url)}`, '_blank');
        }

        function shareOnWhatsApp() {
            const url = window.location.href;
            const text = encodeURIComponent(pageTitle + ' ‚Äî ' + url);
            window.open(`https://wa.me/?text=${text}`, '_blank');
        }

        function shareViaEmail() {
            const url = window.location.href;
            window.location.href = `mailto:?subject=${encodeURIComponent(pageTitle)}&body=${encodeURIComponent('Check this out: ' + url)}`;
        }

        window.addEventListener('scroll', () => {
            const backToTop = document.querySelector('.back-to-top');
            if (window.scrollY > 300) {
                backToTop.classList.add('visible');
            } else {
                backToTop.classList.remove('visible');
            }
        });

        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function(e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) {
                    target.scrollIntoView({ behavior: 'smooth' });
                }
            });
        });

        // Feedback widget
        document.getElementById('feedbackPageUrl').value = window.location.href;
        function toggleFeedback() {
            document.getElementById('feedbackPanel').classList.toggle('open');
        }
        window.toggleFeedback = toggleFeedback;

        function submitFeedback(e) {
            e.preventDefault();
            const form = document.getElementById('feedbackForm');
            const type = form.querySelector('input[name="type"]:checked');
            const msg = document.getElementById('feedbackMsg').value;
            const email = document.getElementById('feedbackEmail').value;
            const pageUrl = window.location.href;
            const subject = encodeURIComponent('[AI 2030 Report] ' + (type ? type.value : 'Feedback') + ': ' + document.title.split(' - ')[0]);
            const body = encodeURIComponent(
                'Type: ' + (type ? type.value : 'N/A') + '\n' +
                'Page: ' + pageUrl + '\n' +
                'From: ' + (email || 'Anonymous') + '\n\n' +
                'Message:\n' + msg
            );
            window.location.href = 'mailto:narenbizymoms@gmail.com?subject=' + subject + '&body=' + body;
            form.style.display = 'none';
            document.getElementById('feedbackSuccess').style.display = 'block';
            setTimeout(() => {
                document.getElementById('feedbackPanel').classList.remove('open');
                setTimeout(() => {
                    form.style.display = '';
                    form.reset();
                    document.getElementById('feedbackSuccess').style.display = 'none';
                }, 300);
            }, 2000);
        }
        window.submitFeedback = submitFeedback;
    </script>
</body>
</html>
